CARIS LIFE SCIENCES, INC. Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale
CARIS LIFE SCIENCES, INC. (CAI) reported Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale of $0 for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-03.
Financial Statements › Cash Flow › Investing Activities
us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities · last filed 2026-03-03
- CARIS LIFE SCIENCES, INC. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for the quarter ending 2025-12-31 was $0.00.
- CARIS LIFE SCIENCES, INC. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for the quarter ending 2025-09-30 was $0.00.
- CARIS LIFE SCIENCES, INC. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for the quarter ending 2024-12-31 was $0.00.
- CARIS LIFE SCIENCES, INC. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for the quarter ending 2024-09-30 was $0.00.
- CARIS LIFE SCIENCES, INC. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for fiscal 2025 was $0.00, a 100.00% decline from fiscal 2024.
- CARIS LIFE SCIENCES, INC. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for fiscal 2024 was $61.38M, a 79.57% decline from fiscal 2023.
- CARIS LIFE SCIENCES, INC. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for fiscal 2023 was $300.49M.
| Period end | Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale 3 month | Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale 6 month | Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale 9 month | Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale 12 month |
|---|---|---|---|---|
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | $0.00 derived: sum of 2 quarters · filed 2026-03-03 | $0.00 10-K · filed 2026-03-03 | |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $0.00 10-Q · filed 2025-11-05 | ||
| 2025-06-30 | $0.00 10-Q · filed 2025-08-12 | |||
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | $0.00 derived: sum of 2 quarters · filed 2026-03-03 | $61.38M 10-K · filed 2026-03-03 | |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $61.38M 10-Q · filed 2025-11-05 | ||
| 2024-06-30 | $61.38M 10-Q · filed 2025-08-12 | |||
| 2023-12-31 | $300.49M 10-K · filed 2026-03-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| RadNet, Inc. (RDNT) | United States | $5.611B | -229.65 |
| GRAIL, Inc. (GRAL) | United States | $5.591B | -7.78 |
| VERACYTE, INC. (VCYT) | United States | $3.904B | 41.21 |
| Celcuity Inc. (CELC) | United States | $3.887B | -22.62 |
| CareDx, Inc. (CDNA) | United States | $3.174B | 13.21 |
| Fortrea Holdings Inc. (FTRE) | United States | $1.903B | -19.43 |
| Personalis, Inc. (PSNL) | United States | $1.769B | -13.30 |
| CASTLE BIOSCIENCES INC (CSTL) | United States | $1.074B | -37.45 |
| Lumexa Imaging Holdings, Inc. (LMRI) | United States | $0.951B | |
| Fulgent Genetics, Inc. (FLGT) | United States | $0.593B | -6.70 |